^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MaaT033

    i
    Other names: MaaT033, pooled allogeneic fecal microbiotherapy
    Associations

    News

    Trials
    Company:
    MaaT Pharma
    Drug class:
    Microbiome modulator
    Related drugs:
    Associations

    News

    Trials
    6ms
    IASO: Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov)
    P1, N=15, Recruiting, MaaT Pharma | Phase classification: P1b --> P1 | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Sep 2024
    Phase classification • Trial completion date • Trial primary completion date
    |
    MaaT033
    6ms
    Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial) (clinicaltrials.gov)
    P2b, N=387, Recruiting, MaaT Pharma | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MaaT033
    11ms
    Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial) (clinicaltrials.gov)
    P2b, N=387, Not yet recruiting, MaaT Pharma | Trial completion date: Oct 2026 --> Jan 2027 | Initiation date: Jun 2023 --> Sep 2023
    Trial completion date • Trial initiation date
    |
    MaaT033
    over1year
    RESTORATION OF GUT MICROBIOTA DIVERSITY WITH ORAL POOLED FECAL MICROBIOTHERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY: THE PHASE 1B CIMON TRIAL (EBMT 2023)
    The CIMON study results show that MaaT033 is safe, well tolerated and effective for gut microbiota restoration in AML patients receiving IC and ATB. A Phase II trial is planned to evaluate MaaT033 in preventing alloHCT complications.
    Clinical • P1 data • Gut Microbiota
    |
    IL2 (Interleukin 2) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    MaaT033
    over1year
    Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial (ASH 2022)
    For IC, 20 patients received cytarabine associated with an anthracycline, 1 patient received azacytidine. Conclusion The CIMON study results show that MaaT033 is safe, well tolerated and effective for gut microbiota restoration in AML patients receiving IC and ATB. A Phase II/III trial is planned to evaluate MaaT033 in preventing allo-HSCT complications.
    Clinical • P1 data
    |
    IL2 (Interleukin 2)
    |
    cytarabine • azacitidine • MaaT033